Category: iRhythm Technologies Inc.
Kevin King, CEO of Silicon Valley digital health company iRhythm, tells MassDevice about the promise of Big Data and how remote patient monitoring can reveal intricate details of the habits of the heart.
Digital health is all the rage in Silicon Valley, especially as consumer technology's biggest players are getting more interested in tracking health and fitness. But for companies like iRhythm, the health side of the equation comes first.
Here's a look at some of the top funding stories for medical device companies this week: HistoSonics nears close of $14.2M funding for non-invasive ablation; Israel-based Keystone Heart raises $14M for cerebral protection; Ceterix Orthopaedics raises $18M for surgical tools; Allied Minds prepares $140M U.K. IPO to support U.S. R&D; mHealth: iRhythm raises $17M for Zio wearable monitor.
San Francisco-based iRhythm Technologies secures $17 million in in Series E funding in support of its wearable Zio heart monitor.
Remote monitoring startup iRhythm touted a new $17 million Series E funding round in support of its wearable devices, saying it plans to pursue efforts in commercialization, marketing and clinical studies.
The San Francisco company offers continuous cardiac monitoring with its FDA-cleared Zio wearable device and accompanying software. The system is designed to log data on patients' heart rhythms, then process and analyze the data to kick out a report for physicians.
iRhythm Technologies, which includes St. Jude Medical among its backers, lands a $16 million Series D round for its Zio wearable heart monitor.
iRhythm Technologies said it closed a $16 million Series D round for its Zio wearable heart monitor, saying it plans to use the proceeds to further its commercial footprint and research & development efforts.
Led by Norwest Venture Partners, which added partner Casper de Clercq to iRhythm's board, the latest financing including contributions from existing backers New Leaf Ventures, Synergy Life Science Partners and Kaiser Permanente Ventures.
Edwards Lifesciences is on track for mid-teens sales growth for its Sapien heart valve, according to a survey of 30 cardiologists by Leerink Swann analysts.
Edwards Lifesciences (NYSE:EW) is on track for solid growth in the transcatheter aortic valve implant market, according to a survey of cardiologists conducted by Leerink Swann analysts.
, California HealthCare Foundation
, Edwards Lifesciences
, George Washington University
, Intuitive Surgical Inc.
, iRhythm Technologies Inc.
, LuxCath LLC
, SensoMotoric Instruments
, Titan Surgical
, Alcon Inc.
Medical device company Mako Surgical readies a public offering of more than 3 million shares worth more than $40 milion to help commercialize its Rio surgical robot.
Mako Surgical (NSDQ:MAKO) said it's planning to sell some 3 million shares of its own stock in an offering worth about $40 million.*